



Medicinal Cannabis and Chronic Pain

Module 2: Education for Clinicians

Introduction

Washington State Legislature. (2015). SB 5052 – Medical Marijuana – Regulation. Retrieved August 5, 2020 from <http://lawfilesexternal.wa.gov/biennium/2015-16/Pdf/Bills/Session%20Laws/Senate/5052-S2.SL.pdf>

Washington State Department of Health (n.d.). Medical Marijuana. Retrieved August 5, 2020 from <http://www.doh.wa.gov/YouandYourFamily/Marijuana/MedicalMarijuana/AuthorizationPracticeGuidelines>

Section 1: Considering Medicinal Cannabis

Aggarwal, S.K., Carter, G.T., Sullivan, M.D., Zumbrennen, C., Morrill, R., & Mayer, J.D. (2013). Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. *American Journal of Hospice and Palliative Care*, 30(6), 523-531. View abstract: <http://dx.doi.org/10.1177/1049909112454215>

Carlini, B.H., Garrett, S.B., & Carter, G.T. (2019). Medicinal cannabis: A survey among health care providers in Washington State. *American Journal of Hospice and Palliative Care*, 34(1), 85-91. View abstract: <http://dx.doi.org/10.1177/1049909115604669>

Grant, I., Atkinson, J.H., Gouaux, B., & Wilsey, B. (2012). Medical marijuana: clearing away the smoke. *Open Neurology Journal*, 6, 18-25. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/>

Kaplan, L., Klein, T., Wilson, M., & Graves, J. (2020). Knowledge, practices, and attitudes of Washington State health care professionals regarding medical cannabis. *Cannabis and Cannabinoid Research*, 5(2), 172-182. View abstract: <https://doi.org/10.1089/can.2019.0051>

MacCallum, C.A. & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.004>

Section 2: Relative Contraindications

Abramovici, H. (2013). Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa, ON: Health Canada. Free online: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf



- Aggarwal, S.K. (2013). Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clinical Journal of Pain*, 29(2), 162-171. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/22367503>
- Goyal, H., Awad, H.H., & Ghali, J.K. (2017). Role of cannabis in cardiovascular disorders. *Journal of Thoracic Disease*, 9(7), 2079-2092. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542986/>
- Grant, I., Atkinson, J.H., Gouaux, B., & Wilsey, B. (2012). Medical marijuana: clearing away the smoke. *Open Neurology Journal*, 6, 18-25. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/>
- Humeniuk, R., Henry-Edwards, S., Ali, R., Poznyak, V., & Monteiro, M. (2010). *The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Manual for use in primary care*. Geneva: World Health Organization. Free online: http://whqlibdoc.who.int/publications/2010/9789241599382_eng.pdf?ua=1
- Joy, J.E., Watson, S.J., & Benson, J.A. (1999). *Marijuana and Medicine: Assessing the Science Base*. Washington, DC: National Academy of Sciences, Institute of Medicine. Free online: http://www.nap.edu/openbook.php?record_id=6376
- Kariyanna, P.T., Wengrofsky, P., Jayarangaiah, A., Haseeb, S., Salciccioli, L., Hegde, S., Marmur, J.D., Soliman, Y., Al-Bayati, S., & McFarlane, S.I. (2019). Marijuana and cardiac arrhythmias: A scoping study. *International Journal of Clinical Research & Trials*, 4(1), 132. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774643/>
- MacCallum, C.A. & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.004>
- Mittleman, M.A., Lewis, R.A., Maclure, M., Sherwood, J.B., & Muller, J.E. (2001). Triggering myocardial infarction by marijuana. *Circulation*, 103(23), 2805-9. Free online: <http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=11401936>
- National Academies of Sciences, Engineering, and Medicine. (2017). *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press. View abstract: <https://doi.org/10.17226/24625>
- U.S. Office of the Surgeon General. (2019). U.S. Surgeon General's Advisory: Marijuana and the developing brain. Retrieved on August 5, 2020 from <https://www.hhs.gov/surgeongeneral/reports-and-publications/addiction-and-substance-misuse/advisory-on-marijuana-use-and-developing-brain/index.html>
- Wan, C., Tan, M.B., Lo, C., Jong, A., Xing, L., FitzGerald M.J., Vollmer, W.M., Buist, S.A., Sin, D.D., & Vancouver Burden of Obstructive Lung Disease (BOLD) Research Group. (2009). Marijuana and chronic obstructive lung disease: a population-based study. *Canadian Medical Association Journal*, 180(8), 814-820. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2665947/>



Wang, T., Collet, J., Shapiro, S., & Ware, M.A. (2008). Adverse effects of medical cannabinoids: A systemic review. *Canadian Medical Association Journal*, 178(13), 1669-1678. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/>

Ware, M.A., Wang, T., Shapiro, S., Collet, J., & COMPASS study team. (2015). Cannabis for the management of pain: assessment of safety study (COMPASS). *Controlled Clinical Trial*, 16(12), 1233-1242. Free online: [https://linkinghub.elsevier.com/retrieve/pii/S1526-5900\(15\)00837-8](https://linkinghub.elsevier.com/retrieve/pii/S1526-5900(15)00837-8)

Section 3: Patient Education

Abramovici, H. (2013). Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa, ON: Health Canada. Free online: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf

Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., & Benowitz, N.L. (2011). Cannabinoid-opioid interaction in chronic pain. *Clinical Pharmacology & Therapeutics*, 90(6), 844-51. View abstract: <http://dx.doi.org/10.1038/clpt.2011.188>

Abuhasira, R., Schleider, L.B., Mechoulam, R., & Novack, V. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. *European Journal of Internal Medicine*, 49, 44-50. View abstract: <https://doi.org/10.1016/j.ejim.2018.01.019>

Aggarwal, S.K. (2013). Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clinical Journal of Pain*, 29(2), 162-171. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/22367503>

Aggarwal, S.K., Carter, G.T., Sullivan, M.D., Morrill, R., ZumBrunnen, C., & Mayer, J.D. (2008). Characteristics of patients with chronic pain accessing treatment with medicinal cannabis in Washington State. *Journal of Opioid Management*, 5(5), 257-286. View abstract: <https://doi.org/10.5055/jom.2009.0028>

Al-Shammari, M., Herrera, K., Liu, X., Gisi, B., Yamashita, T., Han, K., Azab, M., Mashiana, H., Maklad, M., Farooqui, M.T., Makar, R., & Yoo, J.W. (2017). Effects of the 2009 medical cannabinoid legalization policy on hospital use for cannabinoid dependency and persistent vomiting. *Clinical Gastroenterology and Hepatology*, 15(12), 1876-1881. View abstract: <https://doi.org/10.1016/j.cgh.2017.06.055>

Alsherbiny, M.A. & Li, C.G. (2018). Medicinal cannabis-potential drug interactions. *Medicines*, 6(1), 3. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6473892/>

Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009). Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clinical Neuropharmacology*, 32(1), 41-7. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/18978501>



Bonn-Miller, M.O., Loflin, M.J.E., Thomas, B.F., Marcu, J.P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. *JAMA*, 318(17), 1708–1709. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818782/>

Carter, G.T., Flanagan, A., Earleywine, M., Abrams, D.I., Aggarwal, S.K., Grinspoon, L. (2011). Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. *American Journal of Hospice and Palliative Medicine*, 28(5), 297-303. View abstract: <https://doi.org/10.1177/1049909111402318>

Chepyala, P. & Olden, K.W. (2008). Nausea and vomiting. *Current Treatment Options in Gastroenterology*, 11(2), 135-44. View abstract: <https://doi.org/10.1007/s11938-008-0026-6>

Cichewicz, D.L. (2004). Synergistic interactions between cannabinoid and opioid analgesics. *Life Sciences*, 74(11), 1317-24. View abstract: <http://dx.doi.org/10.1016/j.lfs.2003.09.038>

Gruber, S.A., Sagar, K.A., Dahlgren, M.K., Gonenc, A., Smith, R.T., Lambros, A.M., Cabrera, K.B., & Lukas, S.E. (2018). The grass might be greener: Medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. *Frontiers in Pharmacology*, 8, 983. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5776082/>

Hall, W. (2015). What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? *Addiction*, 110(1), 19-35. View abstract: <https://doi.org/10.1111/add.12703>

Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F., Koehl, M., Abrous, D.N., Mendizabal-Zubiaga, J., Grandes, P., Liu, Q., Bai, G., Wang, W., Xiong, L., Ren, W., Marsicano, G., & Zhang, X. (2012). Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. *Cell*, 148(5), 1039-50. View abstract: <http://dx.doi.org/10.1016/j.cell.2012.01.037>

Hazekamp, A. (2018). The trouble with CBD oil. *Medical Cannabis and Cannabinoids*, 1, 65-72. View abstract: <http://dx.doi.org/10.1159/000489287>

Howard, I. (2019). Cannabis hyperemesis syndrome in palliative care: A case study and narrative review. *Journal of Palliative Medicine*, 22(10), 1227-31. View abstract: <https://doi.org/10.1089/jpm.2018.0531>

Jikomes, N. & Zoorob, M. (2018). The cannabinoid content of legal cannabis in Washington State varies systematically across testing facilities and popular consumer products. *Scientific Reports* 8, 4519. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852027/>

Kirkham, T.C. (2009). Cannabinoids and appetite: food craving and food pleasure. *Internal Review of Psychiatry*, 21(2), 163-171. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/19367510>

Le Strat, Y., Le Foll, B. (2011). Obesity and cannabis use: results from 2 representative national surveys. *American Journal of Epidemiology*, 174(8):929-933. Free online: <http://aje.oxfordjournals.org/content/174/8/929.long>



- Lucas, P., Baron, E.P., & Jikomes, N. (2019). Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. *Harm Reduction Journal*, 16(1), 9. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6350348/>
- MacCallum, C.A. & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.004>
- MacDonald, E. & Adams, A. (2019). The use of medical cannabis with other medications: A review of safety and guidelines – An update. In: Canadian Agency for Drugs and Technologies in Health, Ottawa, ON. Free online: <https://pubmed.ncbi.nlm.nih.gov/31721548/>
- Mead, A. (2019). Legal and regulatory issues governing cannabis and cannabis-derived products in the united states. *Frontiers in Plant Science*, 10, 697. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590107/>
- Morgan, C.J.A., Schafer, G., Freeman, T.P., & Curran, H.V. (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. *British Journal of Psychiatry*, 197(4), 285-290. Free online: <http://bjp.rcpsych.org/content/197/4/285.long>
- Multiple Sclerosis Trust. (2015, updated 2019). Sativex (nabiximols). Retrieved on August 5, 2020 from <https://www.mstrust.org.uk/a-z/sativex-nabiximols>
- Nicolson, S.E., Denysenko, L., Mulcare, J.L., Vito, J.P., & Chabon, B. (2012). *Psychosomatics*, 53(3), 212-9. View abstract: <https://doi.org/10.1016/j.psym.2012.01.003>
- Notcutt, W., Langford, R., Davies, P., Ratcliffe, S., & Potts, R. (2012). A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). *Multiple Sclerosis*, 18(2), 219-228. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/21878454>
- Nourbakhsh, M., Miller, A., Gofton, J., Jones, G., & Adeagbo, B. (2019). Cannabinoid hyperemesis syndrome: Reports of fatal cases. *Journal of Forensic Science*, 64(1), 270-274. View abstract: <https://doi.org/10.1111/1556-4029.13819>
- Pacey A.A., Povey, A.C., Clyma, J., McNamee, R., Moore, H.D., Baillie, H., Cherry, N.M., & Participating Centres of Chaps-UK. (2014). Modifiable and non-modifiable risk factors for poor sperm morphology. *Human Reproduction*, 29(8), 1629-1636. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/24899128>
- Patel, R.S., Patel, J., Jaladi, P.R., Bhimanadham, N.N., Imran, S., & Tankersley, W.E. (2019). Burden of persistent vomiting with cannabis use disorder: Report from 55,549 hospitalizations in the United States. *Psychosomatics*, 60(6), 549-55. View abstract: <https://doi.org/10.1016/j.psym.2019.07.003>



Penner, E.A., Buettner, H., & Mittleman, M.A. (2013). The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. *American Journal of Medicine*, 126(7), 583-589. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/23684393>

Robson, P. (2011). Abuse potential and psychoactive effects of δ -9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. *Expert Opinion on Drug Safety*, 10(5):675-685. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/21542664>

Sagar, K.A. & Gruber, S.A. (2018). Marijuana matters: Reviewing the impact of marijuana on cognition, brain structure and function, and exploring policy implications and barriers to research. *Internal Review of Psychiatry*, 30(3), 251-267. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6455965/>

Sagar, K.A. & Gruber, S.A. (2019). Interactions between recreational cannabis use and cognitive function: lessons from functional magnetic resonance imaging. *Annals of the New York Academy of Sciences*, 1451(1), 42-70. View abstract: <https://pubmed.ncbi.nlm.nih.gov/30426517/>

Schleider, L.B., Mechoulam, R., Lederman, V., Hilou, M, Lencovsky, O., Betzalel, O., Shbiro, L., & Novack, V. (2018). Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. *European Journal of Internal Medicine*, 49, 37-43. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.023>

Velez, L.I., O'Connell, E., Rice, J., & Benitez, F. (2018). Adverse reactions to cannabis and cannabinoids. *Emergency Medicine Reports*. Retrieved August 8, 2020 from <https://www.reliamedia.com/articles/143406-adverse-reactions-to-cannabis-and-cannabinoids>

Vigano, D., Rubino, T., & Parolaro, D. (2005). Molecular and cellular basis of cannabinoid and opioid interactions. *Pharmacology Biochemistry and Behavior*, 81(2), 360-8. View abstract: <http://dx.doi.org/10.1016/j.pbb.2005.01.021>

Volkow, N.D., Baler, R.D., Compton, W.M., & Weiss, S.R. (2014). Adverse health effects of marijuana use. *New England Journal of Medicine*, 370(23), 2219-27. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4827335/>

Watanabe, K., Motoya, E., Matsuzawa, N., Funahashi, T., Kimura, T., Matsunaga, T., Arizono, K., & Yamamoto, I. (2005). Marijuana extracts possess the effects like the endocrine disrupting chemicals. *Toxicology*, 206(3), 471-8. View abstract: <https://pubmed.ncbi.nlm.nih.gov/15588936/>

Ware, M.A., Wang, T., Shapiro, S., Collet, J., & COMPASS study team. (2015). Cannabis for the management of pain: assessment of safety study (COMPASS). *Controlled Clinical Trial*, 16(12), 1233-1242. Free online: [https://linkinghub.elsevier.com/retrieve/pii/S1526-5900\(15\)00837-8](https://linkinghub.elsevier.com/retrieve/pii/S1526-5900(15)00837-8)

Washington State Department of Agriculture. (n.d.). Hemp CBD in Food. Retrieved August 5, 2020 from <https://agr.wa.gov/departments/food-safety/food-safety/hemp-cbd-in-food>

Welch, S.P. & Eads, M. (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. *Brain Research*, 848(1-2), 183-90. View abstract: [http://dx.doi.org/10.1016/s0006-8993\(99\)01908-3](http://dx.doi.org/10.1016/s0006-8993(99)01908-3)



Wilson-Morkeh, H., Al-Abdulla, A., Sien, L., Mohamed, H., & Youngstein, T. (2020). Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice. *Rheumatology*, 59(1), 249-251. View abstract: <http://dx.doi.org/10.1093/rheumatology/kez304>

Section 4: Beginning Treatment

Abramovici, H. (2013). Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Ottawa, ON: Health Canada. Free online: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/marihuana/med/infoprof-eng.pdf

Abrams, D.I., Vizoso, H.P., Shade, S.B., Jay, C., Kelly, M.E., & Benowitz, N.L. (2007). Vaporization as a smokeless cannabis delivery system: a pilot study. *Clinical Pharmacology & Therapeutics*, 82(5), 572-578. View abstract: <http://dx.doi.org/10.1038/sj.clpt.6100200>

Aggarwal, S.K. (2013). Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clinical Journal of Pain*, 29(2), 162-171. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/22367503>

Carter, G.T. (2014). Clinical applications of cannabis. Presented at the Washington Academy of Pain Management quarterly meeting, Seattle, WA, January 29, 2014.

Carter, G.T., Weydt, P., Kyashna-Tocha, M., & Abrams, D.I. (2004). Medicinal cannabis: rational guidelines for dosing. *IDrugs*, 7(5), 464-470. View abstract: <http://www.ncbi.nlm.nih.gov/pubmed/15154108>

Hazekamp, A. & Heerdink, E.R. (2013). The prevalence and incidence of medicine cannabis on prescription in The Netherlands. *European Journal of Clinical Pharmacology*, 69(8), 1575-80. View abstract: <https://doi.org/10.1007/s00228-013-1503-y>

Lanz, C., Mattsson, J., Soydaner, U., & Brenneisen, R. (2016). Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. *PLoS ONE*, 11, e0147286. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4718604/>

MacCallum, C.A. & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.004>

Russo, E.B. (2016). Current therapeutic cannabis controversies and clinical trial design issues. *Frontiers in Pharmacology*, 7, 309. Free online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022003/>

Russo E.B. & Hohmann A.G. (2013). Role of cannabinoids in pain management. In: Deer, T. & Gordin, V. (eds). *Comprehensive Treatment of Chronic Pain by Medical, Interventional and Behavioral Approaches*, New York, NY, Springer, 181-197.



U.S. Centers for Disease Control and Prevention. (n.d.). Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. Retrieved August 5, 2020 from https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html

Ware, M.A., Wang, T., Shapiro, S., Collet, J., & COMPASS study team. (2015). Cannabis for the management of pain: assessment of safety study (COMPASS). *Controlled Clinical Trial*, 16(12), 1233-1242. Free online: [https://linkinghub.elsevier.com/retrieve/pii/S1526-5900\(15\)00837-8](https://linkinghub.elsevier.com/retrieve/pii/S1526-5900(15)00837-8)

Washington State Liquor and Cannabis Board. (2019). Packaging and Labeling Guide, v. 1.0, Dec. 2019. Retrieved on August 5, 2020 from: <https://lcb.wa.gov/laws/labeling-resources>

Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. *Journal of Pain*, 14(2), 1356-48. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3566631/>

Section 5: Patient Monitoring

Grant, I., Atkinson, J.H., Gouaux, B., & Wilsey, B. (2012). Medical marijuana: clearing away the smoke. *Open Neurology Journal*, 6, 18-25. Free online: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/>

MacCallum, C.A. & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. View abstract: <http://dx.doi.org/10.1016/j.ejim.2018.01.004>